Literature DB >> 18581443

The current clinical management of Huntington's disease.

Wendy Phillips1, Kathleen M Shannon, Roger A Barker.   

Abstract

Huntington's disease is a neurodegenerative condition, characterized by movement disorders, cognitive decline, and psychiatric disturbance. We review the pharmacological management of the various movement disorders associated with the disease, the cognitive decline and the commonly encountered behavioral disturbances. We discuss the nonclassical features of the disease, important in the management of these patients. Nonpharmacological support including genetic counseling and therapy and the importance of palliative care are also addressed. Finally, experimental approaches that may soon impact upon clinical practice are discussed. (c) 2008 Movement Disorder Society.

Entities:  

Mesh:

Year:  2008        PMID: 18581443     DOI: 10.1002/mds.21971

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  38 in total

1.  Longitudinal behavioral, cross-sectional transcriptional and histopathological characterization of a knock-in mouse model of Huntington's disease with 140 CAG repeats.

Authors:  Aaron C Rising; Jia Xu; Aaron Carlson; Vincent V Napoli; Eileen M Denovan-Wright; Ronald J Mandel
Journal:  Exp Neurol       Date:  2010-12-28       Impact factor: 5.330

Review 2.  Experimental surgical therapies for Huntington's disease.

Authors:  Jelle Demeestere; Wim Vandenberghe
Journal:  CNS Neurosci Ther       Date:  2010-12-28       Impact factor: 5.243

3.  Therapeutics in Huntington's Disease.

Authors:  Annie Killoran; Kevin M Biglan
Journal:  Curr Treat Options Neurol       Date:  2012-02-08       Impact factor: 3.598

4.  Tetrabenazine as anti-chorea therapy in Huntington disease: an open-label continuation study. Huntington Study Group/TETRA-HD Investigators.

Authors:  Samuel Frank
Journal:  BMC Neurol       Date:  2009-12-18       Impact factor: 2.474

Review 5.  Silencing human genetic diseases with oligonucleotide-based therapies.

Authors:  Tamara Martínez; Natalia Wright; Marta López-Fraga; Ana Isabel Jiménez; Covadonga Pañeda
Journal:  Hum Genet       Date:  2013-03-14       Impact factor: 4.132

Review 6.  Palliative care and neurology: time for a paradigm shift.

Authors:  Isabel Boersma; Janis Miyasaki; Jean Kutner; Benzi Kluger
Journal:  Neurology       Date:  2014-07-02       Impact factor: 9.910

Review 7.  Pharmacology of epigenetics in brain disorders.

Authors:  Pritika Narayan; Mike Dragunow
Journal:  Br J Pharmacol       Date:  2009-12-15       Impact factor: 8.739

8.  Antioxidants can inhibit basal autophagy and enhance neurodegeneration in models of polyglutamine disease.

Authors:  Benjamin R Underwood; Sara Imarisio; Angeleen Fleming; Claudia Rose; Gauri Krishna; Phoebe Heard; Marie Quick; Viktor I Korolchuk; Maurizio Renna; Sovan Sarkar; Moisés García-Arencibia; Cahir J O'Kane; Michael P Murphy; David C Rubinsztein
Journal:  Hum Mol Genet       Date:  2010-06-21       Impact factor: 6.150

Review 9.  The role of dopamine in Huntington's disease.

Authors:  Carlos Cepeda; Kerry P S Murphy; Martin Parent; Michael S Levine
Journal:  Prog Brain Res       Date:  2014       Impact factor: 2.453

Review 10.  Treatment of Huntington's disease.

Authors:  Samuel Frank
Journal:  Neurotherapeutics       Date:  2014-01       Impact factor: 7.620

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.